Greenwich LifeSciences (NASDAQ:GLSI) Now Covered by Analysts at Noble Financial

Noble Financial assumed coverage on shares of Greenwich LifeSciences (NASDAQ:GLSI) in a research report sent to investors on Wednesday morning, Marketbeat reports. The firm issued an outperform rating and a $45.00 target price on the stock.

Greenwich LifeSciences Stock Performance

NASDAQ GLSI opened at $11.94 on Wednesday. The business’s 50 day moving average price is $10.69 and its 200-day moving average price is $10.60. Greenwich LifeSciences has a fifty-two week low of $8.06 and a fifty-two week high of $16.50. The company has a market cap of $162.74 million, a P/E ratio of -8.78 and a beta of 1.65.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.06). As a group, equities analysts predict that Greenwich LifeSciences will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC bought a new position in shares of Greenwich LifeSciences during the first quarter valued at approximately $126,000. Police & Firemen s Retirement System of New Jersey bought a new position in Greenwich LifeSciences in the 2nd quarter valued at $25,000. Wells Fargo & Company MN increased its stake in Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock worth $32,000 after purchasing an additional 1,008 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Greenwich LifeSciences by 172.0% during the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after purchasing an additional 4,465 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after purchasing an additional 1,322 shares during the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.